Provided by Tiger Trade Technology Pte. Ltd.

Mersana Therapeutics Inc.

29.08
0.0000
Volume:- -
Turnover:20.77M
Market Cap:145.36M
PE:-2.06
High:29.08
Open:29.08
Low:29.08
Close:29.08
52wk High:36.25
52wk Low:5.21
Shares:5.00M
Float Shares:3.75M
Volume Ratio:- -
T/O Rate:- -
Dividend:- -
Dividend Rate:- -
EPS(TTM):-14.0861
EPS(LYR):-14.1163
ROE:-505.14%
ROA:-36.27%
PB:-2.44
PE(LYR):-2.06

Loading ...

Company Profile

Company Name:
Mersana Therapeutics Inc.
Exchange:
NASDAQ
Establishment Date:
- -
Employees:
- -
Office Location:
- -
Zip Code:
- -
Phone:
- -
Fax:
- -
Introduction:
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.